ConductScience.org, home

Paper41300972

Association Between MMR Status and Prognostic Pathological Factors in Endometrioid Endometrial Cancer-A Single-Center Retrospective Study.

Miedziarek C and 6 others. Cancers (Basel), 2025. Cited by 1 paper, by iCite.

Cite this record

ConductScience Library. Association Between MMR Status and Prognostic Pathological Factors in Endometrioid Endometrial Cancer-A Single-Center Retrospective Study. Papers, record 41300972. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41300972

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Association Between MMR Status and Prognostic Pathological Factors in Endometrioid Endometrial Cancer-A Single-Center Retrospective Study.
PubMed
Journal
Cancers (Basel)
PubMed
Year
2025
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
1
iCite
Revised in PubMed
2025-11-30
PubMed

Authors7

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Miedziarek CCezaryhttps://orcid.org/0000-0002-1933-7530
2Bochyński HHubert
3Bociańska KKatarzyna
4Potograbski MMichał
5Tyburski PPiotrhttps://orcid.org/0009-0006-3371-6154
6Zaborowski MPMikołaj Piotrhttps://orcid.org/0000-0002-4400-6688
7Nowak-Markwitz EEwahttps://orcid.org/0000-0002-2009-2040

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References38

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
133845554Mismatch repair deficiency and clinicopathological characteristics in endometrial carcinoma: a systematic review and meta-analysis.J Pathol Transl Med2021https://conductscience.org/library/papers/33845554PubMed
235658479TP53 Sequencing and p53 Immunohistochemistry Predict Outcomes When Bevacizumab Is Added to Frontline Chemotherapy in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study.J Clin Oncol2022https://conductscience.org/library/papers/35658479PubMed
336915143The impact of lymphovascular space invasion on survival in early stage low-grade endometrioid endometrial cancer.Eur J Med Res2023https://conductscience.org/library/papers/36915143PubMed
437958361MLH1 Methylation Testing as an Integral Component of Universal Endometrial Cancer Screening-A Critical Appraisal.Cancers (Basel)2023https://conductscience.org/library/papers/37958361PubMed
530561762Mismatch repair deficiency identifies patients with high-intermediate-risk (HIR) endometrioid endometrial cancer at the highest risk of recurrence: A prognostic biomarker.Cancer2019https://conductscience.org/library/papers/30561762PubMed
638256131Mismatch Repair Deficiency as a Predictive and Prognostic Biomarker in Endometrial Cancer: A Review on Immunohistochemistry Staining Patterns and Clinical Implications.Int J Mol Sci2024https://conductscience.org/library/papers/38256131PubMed
739191994Aberrant p53 immunostaining patterns in breast carcinoma of no special type strongly correlate with presence and type of TP53 mutations.Virchows Arch2024https://conductscience.org/library/papers/39191994PubMed
832060377Clinicopathological significance of deficient DNA mismatch repair and MLH1 promoter methylation in endometrioid endometrial carcinoma.Mod Pathol2020https://conductscience.org/library/papers/32060377PubMed
932582376Clinicopathologic features of endometrial cancer with mismatch repair deficiency.Ecancermedicalscience2020https://conductscience.org/library/papers/32582376PubMed
1035752743p53 immunohistochemistry in endometrial cancer: clinical and molecular correlates in the PORTEC-3 trial.Mod Pathol2022https://conductscience.org/library/papers/35752743PubMed
1123552806Women 50 years or younger with endometrial cancer: the argument for universal mismatch repair screening and potential for targeted therapeutics.Int J Gynecol Cancer2013https://conductscience.org/library/papers/23552806PubMed
1234431253MLH1 promoter hypermethylation predicts poorer prognosis in mismatch repair deficiency endometrial carcinomas.J Gynecol Oncol2021https://conductscience.org/library/papers/34431253PubMed
1340361433Assessment of p53 in Endometrial Carcinoma Biopsy and Corresponding Hysterectomy Cases in a Real-World Setting: Which Cases Need Molecular Work-Up?Cancers (Basel)2025https://conductscience.org/library/papers/40361433PubMed
1436936577Endometrial cancer: molecular classification and future treatments.BMJ Med2022https://conductscience.org/library/papers/36936577PubMed
1536878570Immunotherapy in endometrial cancer.Int J Gynecol Cancer2023https://conductscience.org/library/papers/36878570PubMed
1639707379Prognostic factors and survival outcomes of immunohistochemically detection based-molecular subtypes of endometrial cancer-analysis of 576 clinical cases.Diagn Pathol2024https://conductscience.org/library/papers/39707379PubMed
1739685500The Role of Immunotherapy in MMR-Deficient Endometrial Carcinoma: State of the Art and Future Perspectives.J Clin Med2024https://conductscience.org/library/papers/39685500PubMed
1838892080Molecular Classification of Endometrial Cancer and Its Impact on Therapy Selection.Int J Mol Sci2024https://conductscience.org/library/papers/38892080PubMed
1940334309Impact of mismatch repair (MMR) status on recurrence in high intermediate risk endometrial cancer.Gynecol Oncol2025https://conductscience.org/library/papers/40334309PubMed
2024092993Overall survival and disease-free survival in endometrial cancer: prognostic factors in 276 patients.Onco Targets Ther2013https://conductscience.org/library/papers/24092993PubMed

See all 38 referencesDownload CSV of references

Cited by1

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1 citation.

PMIDTitleJournalYearIn Papers
42739604Serum Trefoil Factor 3 in Endometrioid Endometrial Carcinoma: Exploratory Diagnostic Value and Association with Lymphovascular Space Invasion.J Clin Med2026https://conductscience.org/library/papers/42739604

Source PubMed

Download CSV of cited by

Genes6

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
EREG2069PubTator's text mininghttps://conductscience.org/library/genes/2069NCBI Gene
ESR12099PubTator's text mininghttps://conductscience.org/library/genes/2099NCBI Gene
MLH14292PubTator's text mininghttps://conductscience.org/library/genes/4292NCBI Gene
PGR5241PubTator's text mininghttps://conductscience.org/library/genes/5241NCBI Gene
PMS25395PubTator's text mininghttps://conductscience.org/library/genes/5395NCBI Gene
TP537157PubTator's text mininghttps://conductscience.org/library/genes/7157NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41300972

GET https://conductscience.org/api/papers/v1/41300972/references?page=2